Ausgabe 6/2011
Inhalt (38 Artikel)
Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity
David J Drasin, Tyler P Robin, Heide L Ford
The microenvironment in breast cancer progression: biology and implications for treatment
Andrew E Place, Sung Jin Huh, Kornelia Polyak
Epigenetics in breast cancer: what's new?
Yi Huang, Shweta Nayak, Rachel Jankowitz, Nancy E Davidson, Steffi Oesterreich
Clinical relevance and biology of circulating tumor cells
Natalia Bednarz-Knoll, Catherine Alix-Panabières, Klaus Pantel
Mammographic density and breast cancer risk: current understanding and future prospects
Norman F Boyd, Lisa J Martin, Martin J Yaffe, Salomon Minkin
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Todd W Miller, Brent N Rexer, Joan T Garrett, Carlos L Arteaga
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, Benjamin Esterni, Daniel Serin, Pierre Kerbrat, Fabrice Andre, Pascal Finetti, Emmanuelle Charafe-Jauffret, Anne-Laure Martin, Mario Campone, Patrice Viens, Daniel Birnbaum, Frédérique Penault-Llorca, François Bertucci
ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma
Arindam Banerjee, Zheng-Sheng Wu, PengXu Qian, Jian Kang, Vijay Pandey, Dong-Xu Liu, Tao Zhu, Peter E Lobie
Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth
Takashi Nishioka, Hyun-Seok Kim, Ling-Yu Luo, Yi Huang, Jinjin Guo, Chang Yan Chen
Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion
Bernadette C Victor, Arulselvi Anbalagan, Mona M Mohamed, Bonnie F Sloane, Dora Cavallo-Medved
Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis
Xiaohui Bi, Meera Hameed, Neena Mirani, Erica Maria Pimenta, Jason Anari, Betsy J Barnes
Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance
H Raza Ali, Sarah-Jane Dawson, Fiona M Blows, Elena Provenzano, Paul D Pharoah, Carlos Caldas
New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours
Richard D Iggo
'Omic approaches to preventing or managing metastatic breast cancer
Obi L Griffith, Joe W Gray
Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study
Sharon N Teraoka, Jonine L Bernstein, Anne S Reiner, Robert W Haile, Leslie Bernstein, Charles F Lynch, Kathleen E Malone, Marilyn Stovall, Marinela Capanu, Xiaolin Liang, Susan A Smith, Josyf Mychaleckyj, Xuanlin Hou, Lene Mellemkjaer, John D Boice Jr, Ashley Siniard, David Duggan, Duncan C Thomas
CHEK2 contribution to hereditary breast cancer in non-BRCAfamilies
Alexis Desrichard, Yannick Bidet, Nancy Uhrhammer, Yves-Jean Bignon
Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
Shinichiro Kashiwagi, Masakazu Yashiro, Tsutomu Takashima, Naoki Aomatsu, Katsumi Ikeda, Yoshinari Ogawa, Tetsuro Ishikawa, Kosei Hirakawa
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
Barbara Adamo, Allison M Deal, Emily Burrows, Joseph Geradts, Erika Hamilton, Kimberly L Blackwell, Chad Livasy, Karen Fritchie, Aleix Prat, J Chuck Harrell, Matthew G Ewend, Lisa A Carey, C Ryan Miller, Carey K Anders
Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis
Lorena Hernandez, Marco AO Magalhaes, Salvatore J Coniglio, John S Condeelis, Jeffrey E Segall
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Nathan R West, Katy Milne, Pauline T Truong, Nicol Macpherson, Brad H Nelson, Peter H Watson
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L Nordstrom, Sergey Gorlatov, Wenjun Zhang, Yinhua Yang, Ling Huang, Steve Burke, Hua Li, Valentina Ciccarone, Tengfei Zhang, Jeffrey Stavenhagen, Scott Koenig, Stanford J Stewart, Paul A Moore, Syd Johnson, Ezio Bonvini
β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer
Hicham Lahlou, William J Muller
Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2
Nyam-Osor Chimge, Sanjeev K Baniwal, Gillian H Little, Yi-bu Chen, Michael Kahn, Debu Tripathy, Zea Borok, Baruch Frenkel
Variants on the promoter region of PTEN affect breast cancer progression and patient survival
Tuomas Heikkinen, Dario Greco, Liisa M Pelttari, Johanna Tommiska, Pia Vahteristo, Päivi Heikkilä, Carl Blomqvist, Kristiina Aittomäki, Heli Nevanlinna
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Teresa Puig, Helena Aguilar, Sílvia Cufí, Glòria Oliveras, Carlos Turrado, Sílvia Ortega-Gutiérrez, Bellinda Benhamú, María Luz López-Rodríguez, Ander Urruticoechea, Ramon Colomer
Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion
Narendra V Sankpal, John D Mayfield, Mike W Willman, Timothy P Fleming, William E Gillanders
Long-term prognosis of breast cancer detected by mammography screening or other methods
Tiina Lehtimäki, Mikael Lundin, Nina Linder, Harri Sihto, Kaija Holli, Taina Turpeenniemi-Hujanen, Vesa Kataja, Jorma Isola, Heikki Joensuu, Johan Lundin
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
Richa Tiwary, Weiping Yu, Linda A deGraffenried, Bob G Sanders, Kimberly Kline
A genome-wide linkage study of mammographic density, a risk factor for breast cancer
Celia MT Greenwood, Andrew D Paterson, Linda Linton, Irene L Andrulis, Carmel Apicella, Apostolos Dimitromanolakis, Valentina Kriukov, Lisa J Martin, Ayesha Salleh, Elena Samiltchuk, Rashmi V Parekh, Melissa C Southey, Esther M John, John L Hopper, Norman F Boyd, Johanna M Rommens
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
Anna Marie Mulligan, Fergus J Couch, Daniel Barrowdale, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Mark Robson, Mark Sherman, Amanda B Spurdle, Barbara Wappenschmidt, Andrew Lee, Lesley McGuffog, Sue Healey, Olga M Sinilnikova, Ramunas Janavicius, Thomas vO Hansen, Finn C Nielsen, Bent Ejlertsen, Ana Osorio, Iván Muñoz-Repeto, Mercedes Durán, Javier Godino, Maroulio Pertesi, Javier Benítez, Paolo Peterlongo, Siranoush Manoukian, Bernard Peissel, Daniela Zaffaroni, Elisa Cattaneo, Bernardo Bonanni, Alessandra Viel, Barbara Pasini, Laura Papi, Laura Ottini, Antonella Savarese, Loris Bernard, Paolo Radice, Ute Hamann, Martijn Verheus, Hanne EJ Meijers-Heijboer, Juul Wijnen, Encarna B Gómez García, Marcel R Nelen, C Marleen Kets, Caroline Seynaeve, Madeleine MA Tilanus-Linthorst, Rob B van der Luijt, Theo van Os, Matti Rookus, Debra Frost, J Louise Jones, D Gareth Evans, Fiona Lalloo, Ros Eeles, Louise Izatt, Julian Adlard, Rosemarie Davidson, Jackie Cook, Alan Donaldson, Huw Dorkins, Helen Gregory, Jacqueline Eason, Catherine Houghton, Julian Barwell, Lucy E Side, Emma McCann, Alex Murray, Susan Peock, Andrew K Godwin, Rita K Schmutzler, Kerstin Rhiem, Christoph Engel, Alfons Meindl, Ina Ruehl, Norbert Arnold, Dieter Niederacher, Christian Sutter, Helmut Deissler, Dorothea Gadzicki, Karin Kast, Sabine Preisler-Adams, Raymonda Varon-Mateeva, Ines Schoenbuchner, Britta Fiebig, Wolfram Heinritz, Dieter Schäfer, Heidrun Gevensleben, Virginie Caux-Moncoutier, Marion Fassy-Colcombet, François Cornelis, Sylvie Mazoyer, Mélanie Léoné, Nadia Boutry-Kryza, Agnès Hardouin, Pascaline Berthet, Danièle Muller, Jean-Pierre Fricker, Isabelle Mortemousque, Pascal Pujol, Isabelle Coupier, Marine Lebrun, Caroline Kientz, Michel Longy, Nicolas Sevenet, Dominique Stoppa-Lyonnet, Claudine Isaacs, Trinidad Caldes, Miguel de la Hoya, Tuomas Heikkinen, Kristiina Aittomäki, Ignacio Blanco, Conxi Lazaro, Rosa B Barkardottir, Penny Soucy, Martine Dumont, Jacques Simard, Marco Montagna, Silvia Tognazzo, Emma D'Andrea, Stephen Fox, Max Yan, Tim Rebbeck, Olufunmilayo I Olopade, Jeffrey N Weitzel, Henry T Lynch, Patricia A Ganz, Gail E Tomlinson, Xianshu Wang, Zachary Fredericksen, Vernon S Pankratz, Noralane M Lindor, Csilla Szabo, Kenneth Offit, Rita Sakr, Mia Gaudet, Jasmine Bhatia, Noah Kauff, Christian F Singer, Muy-Kheng Tea, Daphne Gschwantler-Kaulich, Anneliese Fink-Retter, Phuong L Mai, Mark H Greene, Evgeny Imyanitov, Frances P O'Malley, Hilmi Ozcelik, Gordon Glendon, Amanda E Toland, Anne-Marie Gerdes, Mads Thomassen, Torben A Kruse, Uffe Birk Jensen, Anne-Bine Skytte, Maria A Caligo, Maria Soller, Karin Henriksson, von Anna Wachenfeldt, Brita Arver, Marie Stenmark-Askmalm, Per Karlsson, Yuan Chun Ding, Susan L Neuhausen, Mary Beattie, Paul DP Pharoah, Kirsten B Moysich, Katherine L Nathanson, Beth Y Karlan, Jenny Gross, Esther M John, Mary B Daly, Saundra M Buys, Melissa C Southey, John L Hopper, Mary Beth Terry, Wendy Chung, Alexander F Miron, David Goldgar, Georgia Chenevix-Trench, Douglas F Easton, Irene L Andrulis, Antonis C Antoniou
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
Elena Muraro, Debora Martorelli, Elisa Turchet, Gianmaria Miolo, Simona Scalone, Elisa Comaro, Renato Talamini, Katy Mastorci, Davide Lombardi, Tiziana Perin, Antonino Carbone, Andrea Veronesi, Diana Crivellari, Riccardo Dolcetti
miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells
Yee-Ming Lee, Jen-Yi Lee, Chao-Chi Ho, Qi-Sheng Hong, Sung-Liang Yu, Chii-Ruey Tzeng, Pan-Chyr Yang, Huei-Wen Chen
Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
Johan Staaf, Göran Jönsson, Markus Ringnér, Bo Baldetorp, Åke Borg
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
William Jacot, Evelyne Lopez-Crapez, Simon Thezenas, Romain Senal, Frédéric Fina, Frédéric Bibeau, Gilles Romieu, Pierre-Jean Lamy
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang, Gladys Morrison, Ryan Gillihan, Jun Guo, Robin M Ward, Xiaoyong Fu, Maria F Botero, Nuala A Healy, Susan G Hilsenbeck, Gail Lewis Phillips, Gary C Chamness, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff